Generics bulletin provides its subscribers with up-to-date commercial intelligence about business opportunities in the global generic medicines and biosimilars markets.
Accurate and reliable news reports reveal the strategies of the world’s leading generics companies and analyse their business performance, plans and product portfolios.
Patent and pricing issues, regulatory changes, government initiatives, market opportunities and industry consolidation provide the wider context for Generics bulletin’s comprehensive industry coverage.
With subscribers in nearly 60 countries, Generics bulletin is read by senior executives in all of the world’s leading generics companies, as well as by industry watchers and those supplying active ingredients, goods and services to the global generic and biosimilar medicines industries. Source